LeonaBio, Inc. (LONA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 33.50M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 6.71M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -122.11M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.50M | (m) | $6.71M | $-122.11M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $24.46M | (m) | $5.13M | $-109.94M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $17.50M | (m) | $6.10M | $-102.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $20.16M | (m) | $6.87M | $-39.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $35.26M | (m) | $8.40M | $-62.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $53.75M | (m) | $10.01M | $-82.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $70.68M | (m) | $11.05M | $-100.90M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $84.99M | (m) | $11.05M | $-114.35M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $94.27M | (m) | $10.61M | $-119.77M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $93.73M | (m) | $10.52M | $-123.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $93.79M | (m) | $10.62M | $-125.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $85.35M | (m) | $10.76M | $-129.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $75.11M | (m) | $10.68M | $-118.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $68.30M | (m) | $10.66M | $-110.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $61.46M | (m) | $10.61M | $-104.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $58.85M | (m) | $9.68M | $-89.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $52.59M | (m) | $8.37M | $-83.56M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $49.81M | (m) | $6.38M | $-76.63M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $42.79M | (m) | $4.62M | $-64.02M | $3.00K | (m) | (m) | -21340.67× | Reported |
| 2021-09-30 | $35.36M | (m) | $3.60M | $-54.32M | $2.00K | (m) | (m) | -27161.50× | Reported |
| 2021-06-30 | $30.49M | (m) | $2.61M | $-43.89M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $20.14M | (m) | $1.55M | $-29.51M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $13.29M | (m) | $633.00K | $-20.00M | $367.00K | (m) | (m) | -54.48× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.79M | (m) | $253.00K | $-5.45M | $346.00K | (m) | (m) | -15.75× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |